As one of the four key strategic emerging industries in Xiamen's modern industrial system, the biopharmaceutical industry has risen against the odds, driving revenue to surpass 100 billion yuan for three consecutive years. The city has cultivated and gathered over 1,600 enterprises in the biopharmaceutical and health sector, including 616 national high-tech enterprises and 11 listed companies. After years of development, Xiamen's biopharmaceutical companies have shown strong innovation momentum: Innovax successfully developed the world's first recombinant hepatitis E vaccine and China's first cervical cancer vaccine, both of which have been mass-produced; AmoyDx pioneered the approval and inclusion of China's tumor companion diagnostic products in Japan's national insurance; and Double Medical developed a new type of bone plate that can withstand hundreds of bends. Recently, Xiamen issued the "Implementation Rules for Measures to Accelerate the High-Quality Development of the Biopharmaceutical Industry," further standardizing the disbursement of related reward and subsidy funds to better empower the high-quality development of the city's biopharmaceutical industry.
